Search Results

You are looking at 91 - 100 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Interventional Oncology: Adding Options to the Care of Patients with Cancer

Daniel B. Brown

, radioembolization with yttrium-90 ( 90 Y) microspheres, and thermal ablation, are increasingly being used in the United States. Current indications for these treatments are part of several NCCN Guidelines. Ablation is the preferred treatment modality in renal cell

Full access

The NCCN 2024 Annual Conference

Crystal S. Denlinger and Wui-Jin Koh

-negative breast cancer; localized prostate cancer; MSI-H/dMMR upper and lower gastrointestinal cancers; metastatic non–small cell lung cancer; small cell lung cancer; locally advanced rectal cancer; renal cell carcinoma; metastatic urothelial cancer

Full access

Optimizing Systemic Therapy for Bladder Cancer

Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack

Over the past decade, several advances in systemic therapy for genitourinary cancers have occurred. Since 2005, a total of 7 agents have been approved for metastatic renal cell carcinoma (RCC) based on positive phase III trials. 1 Similarly, 4

Full access

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma

Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary

. ALK fusion genes, including EML4-ALK and STRN-ALK , have been identified in multiple cancer types, including lung adenocarcinoma, colorectal adenocarcinoma, breast cancer, renal cell carcinoma, renal medullary carcinoma, and papillary thyroid

Full access

Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Dong Ding, Huabin Hu, Shuosha Li, Youwen Zhu, Yin Shi, Mengting Liao, Jin Liu, Xu Tian, Aiting Liu, and Jin Huang

. 25691669 10.1200/JCO.2014.58.4904 15. Rini BI , Plimack ER , Stus V , Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma . N Engl J Med 2019 ; 380 : 1116 – 1127 . 10.1056/NEJMoa1816714 30779529 16

Full access

Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review

Andrew J. Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall

.5%), non–small cell lung cancer (n=7; 5.9%), Merkel cell carcinoma (n=3; 2.5%), colorectal cancer (n=3; 2.5%), renal cell carcinoma (n=3; 2.5%), ocular melanoma (n=3; 2.5%), and intrahepatic cholangiocarcinoma (n=1; 0.8%). Table 1. Patient

Full access

Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing

Agda Karina Eterovic, Ossama M. Maher, Joya Chandra, Ken Chen, Jason Huse, and Wafik Zaky

. 19. Kato K Ijiri R Tanaka Y ., Metachronous renal cell carcinoma in a child cured of neuroblastoma . Med Pediatr Oncol 1999 ; 33 : 432 – 433 . 20. Tanaka M Kato K Gomi K . Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene

Full access

NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types

Donald A. Podoloff, Douglas W. Ball, Edgar Ben-Josef, Al B. Benson III, Steven J. Cohen, R. Edward Coleman, Dominique Delbeke, Maria Ho, David H. Ilson, Gregory P. Kalemkerian, Richard J. Lee, Jay S. Loeffler, Homer A. Macapinlac, Robert J. Morgan Jr., Barry Alan Siegel, Seema Singhal, Douglas S. Tyler, and Richard J. Wong

cancer . Urology 2001 ; 57 : 108 – 111 . 70 Kang DE White RL Jr Zuger JH . Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma . J Urol 2004 ; 171 : 1806 – 1809 . 71

Full access

Toward Personalized Guidelines in Bladder Cancer

Peter E. Clark

appreciation of tumor heterogeneity. Ground-breaking work in renal cell carcinoma has shown significant differences in the molecular profile of the primary tumor and metastatic foci within the same patient. 5 Indeed, even within the primary tumor, the

Full access

The Selection of Hormonal Therapy in Prostate Cancer: Who, When, and for How Long?

Charles J. Ryan and Eric J. Small

patients with advanced renal cell carcinoma . Cancer Treat Rep 1980 ; 64 : 343 – 344 . 29 Pienta K Redman BG Esper PS . A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of